Skip to main content

Utilization of Archived Plasma to Detect Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer Patients.

Oh AC, Lee JK, Kim JY, Jin HO, Jung JW, Chang YH, Hong YJ

Publication: Biopreserv Biobank (2019) • Vol 17 • Page 319-325PMID: 30888199View on PubMed

Purpose

This paper investigated the effects of patient gender, diagnosis, chemotherapy treatment status, delay to centrifugation, frozen storage duration of plasma, and cell-free DNA (cfDNA) extraction kit used on determination of epidermal growth factor receptor (EGFR) mutation status of non-small cell lung cancer (NSCLC) patients and compared results of cfDNA analysis to those obtained from tissue or cytology specimens.

Conclusion

The EGFR mutation detection rate was higher in women than men and in patients who had undergone chemotherapy than those who had not and varied significantly according to stage with Stage IV specimens showing the highest mutation burden. However, there was no difference in the EGFR mutation detection rate in plasma based on histologic type. The cfDNA concentration was higher when extracted with the Cobas cfDNA Sample Preparation Kit than the Maxwell ccfDNA Plasma Kit, but there was no difference in the detection rate for EGFR mutations between the two kits. A lower percentage of plasma specimens were found to have EGFR mutations than matched tissue/cytology specimens (19% versus 53.4%, concordance rate of 58.6%). There were no differences in EGFR mutation detection rate or cfDNA concentration in plasma due to a delay to centrifugation (≤4 h versus >4 h) or storage duration (≤12 months, >12 months).

Studies (1)

Purpose

This study investigated the effects of patient gender, diagnosis, chemotherapy treatment status, delay to centrifugation, frozen storage duration of plasma, and cfDNA) extraction kit used on EGFR mutation status analysis of cfDNA from NSCLC patients and compared results to those obtained from tissue or cytology specimens. Blood was collected in K2EDTA tubes from 116 NSCLC patients (median age=65 y; 61 males, 55 females; 86 adenocarcinomas, 1 adenosquamous carcinoma, 1 bronchioalveolar carcinoma, 1 large cell carcinoma, 27 squamous cell carcinomas) diagnosed as Stage I (n=35), II (n=9), III (n=22), or IV (n=50) undergoing chemotherapy treatment (n=50) or not receiving chemotherapy treatment (n=66). Plasma was obtained by centrifugation for 10 minutes at 2000 x g at 4°C within 0-172.7 h of collection. Plasma was immediately stored at -70°C until analysis (average 9.6 – 25.0 mos). cfDNA was extracted using the Cobas cfDNA Sample Preparation Kit or the Maxwell RSC ccfDNA Plasma Kit. cfDNA concentration was measured by fluorometry using the Qubit dsDNA HS Assay Kit. EGFR mutation was detected by real-time PCR using the Cobas EGFR Mutation Test v2. Results were compared with those previously obtained in the tissue or cytology EGFR mutation test (details not provided).

Summary of Findings

The EGFR mutation detection rate was higher in women than men (P=0.035) and in patients who had undergone chemotherapy than those who had not (P=0.030) and varied significantly according to stage (P=0.015) with Stage IV specimens showing the highest mutation burden. However, the EGFR mutational burden did not significantly differ among the different histologic types. The cfDNA concentration was higher when extracted from plasma with the Cobas cfDNA Sample Preparation Kit than the Maxwell ccfDNA Plasma Kit (P<0.001), but there was no difference between the two kits in the detection rate for EGFR mutations. The sensitivity and specificity of the plasma test for mutations identified in matched tissue/cytologic specimens was 33.9% and 98.1%, respectively. A total of 26 EGFR mutations were observed in 22 plasma specimens (19%, 4 specimens with multiple mutations) compared to 65 mutations in 62 tissue/cytology specimens (53.4%, three specimens with multiple mutations) with a concordance rate of 58.6%. The exon 19 deletion was the most frequent mutation observed in the plasma and tissue/cytology specimens (9.5% and 30.2%, respectively) followed by L858R (6.9% and 20.7%, respectively). The T790M mutation was detected in five (4.3%) of the plasma specimens and two tissue/cytology specimens (1.7%) but was positive in both tests for specimens from only one patient. There were no differences in EGFR mutation detection or cfDNA concentration in plasma due to a delay to centrifugation (≤4 h versus >4 h) or storage duration (≤12 months, >12 months).

  • Biospecimens

    FluidBlood
    FluidPlasma
    TissueLung
  • Preservation Types

    Frozen
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    DNAFluorometry
    DNAReal-time qPCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    adenocarcinoma
    adenosquamous carcinoma
    bronchioalveolar carcinoma
    large cell carcinoma
    squamous cell carcinoma
    PreaquisitionOther drugs
    No chemotherapy
    Received chemotherapy
    PreaquisitionPatient gender
    Female
    Male
    PreaquisitionPrognostic factor
    Stage I
    Stage II
    Stage III
    Stage IV
    Biospecimen Aliquots and ComponentsCentrifugation
    Centrifugation delays investigated
    StorageStorage duration
    >12 months
    ≤12 months
    Analyte Extraction and PurificationAnalyte isolation method
    Cobas cfDNA Sample Preparation Kit
    Maxwell RSC ccfDNA Plasma Kit
    Real-time qPCR SpecificTargeted nucleic acid
    EGFR mutation